Department of Cardiology, CardioVascular Center, University Hospital Zurich, Switzerland.
Atherosclerosis. 2011 Oct;218(2):486-92. doi: 10.1016/j.atherosclerosis.2011.06.020. Epub 2011 Jun 17.
We previously reported increased expression of TLR4 on monocytes in thrombi from patients with acute coronary syndromes (ACS). In mice, myeloid related protein (MRP) 8 and MRP14, cytoplasmic proteins of neutrophils and monocytes, activate Toll-like receptor (TLR) 4 during sepsis. In human ACS, we investigated now whether the pro-inflammatory action of MRPs occurs through TLR4 in monocytes derived from thrombi.
Coronary thrombi and peripheral blood of 27 ACS patients were analyzed. CD14(+) monocytes were isolated and incubated with TLR2 ligand PM3SKA, TLR4 ligand lipopolysaccharide (LPS), MRP8, MRP14, or MRP8/14 heterocomplex. Anti-TLR4 antibodies (HTA125) were used to block TLR4 and polymyxin B (PMB) was employed to inhibit endotoxins. Before and after stimulation, the release of TNFα was measured by ELISA and the expression of TLR4 on CD14(+) monocytes was determined by flow cytometry. Further, selected pathways of downstream signaling were analyzed.
MRP8 and MRP8/14 increased release of TNFα in cultures of CD14(+) monocytes, more in cells derived from thrombi compared with matched peripheral blood cells (p<0.001). LPS, MRP8, and MRP8/14, but much less PM3SKA and MRP14 alone, stimulated TNFα release, which can be inhibited by HTA125. MRP8/14 enhanced TLR4 expression on monocytes from thrombi (p<0.001), but not on monocytes from peripheral blood of the same patients.
In ACS, MRP8 and MRP8/14 complex are specific ligands of TLR4, which induce the release of TNFα and probably other pro-inflammatory agents from monocytes. This specific MRP8/14-dependent pathway with striking similarities to sepsis increasing expression of TLR4 in thrombi appears to be involved in the pathogenesis of coronary occlusion and may represent a novel therapeutic target in ACS.
我们之前报道过,在急性冠脉综合征(ACS)患者的血栓中,单核细胞上 TLR4 的表达增加。在小鼠中,髓系相关蛋白(MRP)8 和 MRP14,中性粒细胞和单核细胞的细胞质蛋白,在脓毒症中激活 Toll 样受体(TLR)4。在人类 ACS 中,我们现在研究了 MRP 是否通过血栓衍生的单核细胞上的 TLR4 发挥促炎作用。
分析了 27 例 ACS 患者的冠状动脉血栓和外周血。分离 CD14(+)单核细胞,并用 TLR2 配体 PM3SKA、TLR4 配体脂多糖(LPS)、MRP8、MRP14 或 MRP8/14 异源复合物孵育。使用抗 TLR4 抗体(HTA125)阻断 TLR4,并用多粘菌素 B(PMB)抑制内毒素。刺激前后,通过 ELISA 测量 TNFα 的释放,并用流式细胞术测定 CD14(+)单核细胞上 TLR4 的表达。此外,还分析了下游信号转导的选定途径。
MRP8 和 MRP8/14 在 CD14(+)单核细胞培养物中增加 TNFα 的释放,与匹配的外周血细胞相比,在源自血栓的细胞中增加更多(p<0.001)。LPS、MRP8 和 MRP8/14 但单独的 PM3SKA 和 MRP14 较少,刺激 TNFα 释放,这可以被 HTA125 抑制。MRP8/14 增强了来自血栓的单核细胞上 TLR4 的表达(p<0.001),但对来自同一患者外周血的单核细胞没有影响。
在 ACS 中,MRP8 和 MRP8/14 复合物是 TLR4 的特异性配体,其诱导 TNFα 从单核细胞释放,可能还有其他促炎剂。这种特定的 MRP8/14 依赖性途径与脓毒症中 TLR4 表达增加具有惊人的相似之处,似乎参与了冠状动脉闭塞的发病机制,并可能成为 ACS 的新治疗靶点。